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EFFECTS OF PENFLURIDOL ON INTEGRIN-FAK SIGNALING AND TUMOR CELL
KILLING IN COMBINATION WITH ONCOLYTIC HSV IN GLIOBLASTOMA

Mitra Nair, B.S
Advisory Professor: Balveen Kaur, PhD.
Abstract
Integrins are known to play an important role in activating multiple intracellular pathways, one
of which is focal adhesion kinase (FAK). Phosphorylation of FAK can lead to the activation of
various downstream signaling pathways that can increase tumor cell growth and proliferation,
making it an ideal target for cancer therapeutics. Due to the fact that many FAK inhibitors are
limited in their penetration of the blood brain barrier, we investigated the use of Penfluridol, an
antipsychotic drug known to attenuate integrin expression at a transcriptional level, in
combination with oncolytic herpes simplex I virus (oHSV) in a glioblastoma model. We
examined the effects of oHSV on FAK signaling by looking at FAK phosphorylation at different
time points post-infection and saw that FAK was activated by viral infection at earlier time
points. When combining Penfluridol with oHSV, we saw that at higher drug concentrations there
was a decrease in viral propagation, however combination treatment increased overall tumor cell
killing compared to either treatment alone. Additionally, we know that viral treatment causes
immune cell infiltration leading to viral clearance. Combination of Penfluridol with virus
treatment significantly reduced immune cell migration towards infected cells. To assess the
effects of Penfluridol in vivo, GBM tumors were implanted intracranially in mice and treated
with Penfluridol and oHSV. Survival data and bioluminescence imaging to evaluate virus
replication was collected to examine the efficacy of the combination treatment. Overall, virus
replication was not inhibited by Penfluridol treatment in vivo. Furthermore, mice treated with
both Penfluridol and oHSV survived significantly longer than mice in individual treatment
groups. These findings conclude that Penfluridol has the ability to attenuate integrin and FAK
signaling and increase tumor cell killing when combined with oHSV in vitro. Additionally, we
have seen that the combination treatment of Penfluridol and oHSV can significantly enhance
survival in both immune deficient and immune competent mouse models in vivo.
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Introduction
Glioblastoma (GBM) is currently the most commonly diagnosed primary, malignant
brain tumor. The invasive nature of this tumor makes complete surgical resection with clear
margins extremely difficult to accomplish without negatively affecting normal brain function (1).
In addition to its invasive nature, GBM also secretes various cytokines and growth factors that
encourage the infiltration of tumor supportive immune cells. This ultimately leads to the creation
of a tumor microenvironment (TME) that influences tumor growth and metastasis, along with the
ability for the tumor to resist treatment (2). Despite efforts that have been made towards
developing treatments, the overall prognosis remains poor, making it imperative that other
therapeutic approaches are investigated in order to improve the survival outcome in GBM
patients (3). Oncolytic viral (OV) therapy is an approach that involves the use of either a natural
strain or genetically engineered virus that can enter and replicate specifically in cancer cells. This
will ultimately lead to the lytic destruction of cancer cells causing minimal damage to
surrounding tissues (4). Currently, one of the most studied OV treatments is the use of the herpes
simplex-1 virus (HSV) and the oHSV therapy, Talimogene laherparepvec (T-Vec), which is
currently FDA approved for the treatment of metastatic melanoma (5). Additionally, many other
second generation oHSV vectors are at various stages in clinical trials for GBM treatment
(NCT00028158, NCT02062827, NCT00157703). Despite the numerous advantages of oHSV

therapy, virally induced activation of pathways that can allow for viral clearance and tumor cell
growth can pose an issue for the clinical development and application of viral therapy. Therefore,
it is pertinent that we examine the mechanism behind these activated pathways and consider
using oHSV in combination with another therapy to enhance overall tumor cell death. In this
paper, we will explore the role that oHSV plays in activating integrins and in turn, activating
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FAK which can ultimately allow for tumor cell growth/proliferation and viral clearance.
Integrins are a family of cell surface receptors that bind extracellular matrix (ECM) proteins and
activate numerous intracellular signaling pathways that are known regulate tumor cell
proliferation and survival (6). In addition to their signaling ability, integrins also play a role in
viral entry. The gH/gL complex on the viron envelope interacts with high affinity to integrin
receptors ανβ6 and ανβ8, which then allow the virus to enter the cell via plasma membrane
fusion or endocytosis (7). One of the major pathways that is activated as a result of integrin
engagement is focal adhesion kinase (FAK). FAK is known to regulate many aspects of
metastasis and is overexpressed and activated in a variety of cancers. Furthermore, activation of
FAK can lead to adhesion, migration, and invasion of tumor cells (8). Due to these downstream
effects of integrin activation, we investigated the use of Penfluridol, an FDA approved
antipsychotic drug, which has been shown to reduce integrin expression at a transcriptional level
and decrease tumor cell growth in breast cancer tumor models (9). We hypothesize that
combining oHSV with Penfluridol will decrease downstream activation of FAK, therefore,
decreasing viral clearance, tumor cell survival, and tumor growth in our glioma model (Fig.1).

Fig.1 Graphical representation of hypothesis which illustrates the ability for Penfluridol (PF) to attenuate integrin
and FAK signaling which can ultimately lead to a decrease in tumor growth and viral clearance.
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Materials and Methods
Cell lines and Oncolytic Herpes Simples Virus-1 (oHSV-1)

U251T3, U87ΔEGFR, and Vero cells were maintained in Dulbecco’s Modified Eagle’s
Medium (DMEM; Gendepot, Houston, TX) supplemented with 10% fetal bovine serum (FBS).
U251 cells were obtained from Dr. Erwin G. Van Meir (Emory University, Atlanta, GA) and
U251-T3 (T3) cells were created in our laboratory (May 2009) as a tumorigenic clone of U251
cells by serially passaging these cells three times in mice. U87ΔEGFR cells express a truncated,
constitutively active, mutant form of the epidermal growth factor receptor (EGFRvIII). Patientderived primary GBM cells (GBM8, GBM12, GBM28, GBM43, and GBM1016) were provided
by Dr. Jann N. Sarkaria (Mayo Clinic, Rochester, MN). Primary GBM cells were maintained as
tumor spheres in neurobasal medium supplemented with 2% B27 without vitamin A, human
EGF (20 ng/mL), and basic FGF (20 ng/mL) in low-attachment cell culture flasks. GL261N4
cells and monkey kidney epithelial derived Vero cells were obtained from the ATCC. Primary
GBM cells (February 2019) were authenticated by MD Anderson Cancer Center Characterized
Cell Line Core via STRS profiling and U87ΔEGFR (October 2018), and U251T3 (January 2015)
cells were authenticated by the University of Arizona Genetics Core via STRS profiling. Murine
BV2 microglia were maintained in DMEM supplemented with 2% FBS (2F). BV2 cells were
obtained in January 2009 from J. Godbout (Ohio State University, Columbus, OH). Murine
RAW264.7 macrophages were maintained in RPMI supplemented with 10% FBS. RAW264.7
macrophages were received in June 2010 from S. Tridandapani (Ohio State University,
Columbus, OH). Murine BV2 and RAW264.7 cells have not been authenticated since receipt.
All cells were maintained at 37 °C in a humidified atmosphere with 5% carbon dioxide and with
100 units of penicillin/mL and 0.1 mg of streptomycin/mL (Pen/Strep). All cells were routinely
3

monitored for changes in morphology and growth rate. All cells were confirmed negative
for Mycoplasma. For oncolytic HSV, we used rHSVQ and rHSVQ-IE4/5-Luciferase (rHSVQLuc), which are both disrupted in the UL39 locus and deleted for both copies of the ICP34.5
gene. Viral stocks were generated and titered on Vero cells via standard plaque forming unit
assays.
Western blot analysis and antibodies
Cell lysates were fractionated by SDS-PAGE and transferred to nitrocellulose (NC) membranes.
Blocked membranes were then incubated with antibodies against Anti-integrin alpha V, Antiintegrin alpha 6, Anti-integrin beta 3, Anti-phospho Akt (S473), Anti-phospho p44/p42 MAPK
(Cell Signaling Technology, Waltham, MA), Anti-phospho FAK (Abcam, Cambridge, MA), and
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA) (each diluted 1:1000) ; HRP-conjugated
secondary anti-mouse antibody (each diluted 1:1000) (GE Healthcare, Piscataway, NJ); HRPconjugated secondary goat anti-rabbit antibody (each diluted 1:1000) (Dako, Hamburg,
Germany), and the immunoreactive bands were visualized using enhanced chemiluminescence
(ECL) (GE Healthcare, Piscataway, NJ).
Cell Proliferation Assay
Cells were plated in 96-well plates containing 10000 cells/well in 50uL of 2%FBS-containing
media. Seeded cells were infected at 0.01, 0.05, and 0.1MOI with HSVQ in a volume of 25uL of
2%FBS-containing media and one hour later were treated with 4 different concentrations of
either GSK2256098 or Penfluridol. Cells and virus were incubated for 24-72hpi at 37C, and cell
viability was measured using a cell proliferation kit (Roche) following manufacturer’s protocol.
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Absorbance was measured using a Synergy HT Multi-Mode Microplate reader (Biotek), and cell
viability was measured as a percentage of uninfected control.
Quantitative virus spread by Cytation 5 live imaging
Glioma cells and primary GBM cells were infected with 0.5 MOI of HSVQ. One hour post virus
infection, unbound virus was removed, and cells were treated with Penfluridol at 0.078uM,
0.156uM, 0.3125uM, 0.625uM and 1.25uM for 48 hours. Virus-encoded GFP expression was
monitored every 4 hours for 48 hours using the Cytation 5 live plate reader/imager (BioTek
Instruments). Captured images were analyzed by BioTek Gen5 version 2.06 software program.
Prism (GraphPad) was used for curve fitting.
Cell Migration Assay
Cell migration was evaluated in a 24-well chemotaxis chamber equipped with a polycarbonate
filter with 5 µm pores (Costar, Corning, NY). GBM8 tumor cells were plated in the bottom
chamber and infected for 1 hour at a MOI of 1 and unbound viruses were washed out and treated
with and without Penfluridol (5uM) for 2 hours. Subsequently, serum starved Raw264.7 or BV2
cells were plated in the top chamber and then left to migrate for 6 hours. Following incubation,
cells were fixed and stained.
ELISA
Raw264.7 and BV2 cells were seeded in 6 well- plates and treated with 5uM of Penfluridol. All
assays were performed in triplicate. Cells and media were harvested 24 hours post drug
treatment, centrifuged for 5 minutes at 8,000 rpm, and cell pellets and supernatant conditioned
media were frozen. Murine TNFα was quantified in cell supernatants using the mouse murine
TNFα DuoSet ELISA kit (R&D Systems, Cat# DY410, Minneapolis, MN) according to the
5

manufacturer's recommendations. Serial dilutions of a known concentration of purified
recombinant murine TNFα were used to establish a standard curve.
Xenograft studies
All mouse housing and experiments were performed in accordance with the Subcommittee on
Research Animal Care of the Ohio State University (OSU) and the Animal Welfare Committee
at the University of Texas Health Science Center in Houston guidelines and have been approved
by the Institutional Review Board. Six-week-old outbred female athymic nu/nu mice were
obtained from the Target Validation Shared Resource at the Ohio State University, from which
original breeders (strain #553 and #554) were received from the NCI Frederick facility. NSG and
C57BL/6 mice were obtained from Jackson Laboratory.
Three intracranial tumor studies were done in this paper. For intracranial tumor implantation,
anesthetized mice were fixed in a stereotactic apparatus, and a burr hole was drilled at 2 mm lateral
and 1 mm front to the bregma, to a depth of 3.5 mm. 1x10^5 GBM30 human glioma cells, 1x10^5
GBM12 human glioma cells, and 1x10^5 GL261N4 murine glioma cells were implanted
intracranially. Ten days post tumor cell implantation, mice were randomized and injected with
PBS or 1x10^5 pfu of rHSVQ1-Luc intratumorally. One day before PBS/oHSV injection, GBM12
and GL261N4 implanted mice began daily treatment of DMSO or Penfluridol (10 mg/kg) by oral
gavage, while GBM30 implanted mice began daily treatment of DMSO or Penfluridol (10 mg/kg)
by oral gavage after virus injection. Animals were observed daily and euthanized at the indicated
time points or when they showed signs of morbidity (hunched posture and weight loss).
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In vivo luciferase imaging
Nude mice bearing GBM30 tumors or NSG mice bearing GBM12 tumors were treated with
DMSO or Penfluridol (10 mg/kg) via oral gavage daily starting at day 9 post tumor implantation.
Mice were then treated with PBS or HSVQ1-Luc of 1x10^5 pfu by intratumoral injection 10
days post tumor implantation. Mice were subjected to in vivo luciferase imaging on days 1, 2,
and 3, after the oHSV therapy. Mice were injected with Luciferin solution (25 mg/ml in PBS,
dose of 100 mg/kg, Perkin Elmer, Waltham, MA) by an intraperitoneal injection and
anesthetized. The anesthetized mice were placed on non-fluorescent black paper on the imaging
platform under ZFOV-24 zoom lens-installed IVIS Lumina Series III Pre-clinical in vivo
Imaging System (Perkin Elmer, Waltham, MA) to reduce background noise. Luminescence
intensity was expressed as Averaged Radiance [p/s/cm²/sr], then normalized by tumor volume
(mm3).
Statistical analysis
To compare two independent treatments for continuous endpoints such as viral titers, and cell
viability assay, student’s t test was used. When multiple pairwise comparisons were assessed,
one-way ANOVA was used. To evaluate the synergistic interaction between Penfluridol and
oHSV, an interaction contrast or two-way ANOVA model was applied. Log-rank test was used
to compare survival curves for survival data and Cox regression model was used to evaluate the
interaction between Penfluridol and oHSV on survival data. P values were adjusted for multiple
comparisons by Holms’ procedure. A p value of 0.05 or less was considered statistically
significant.
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Results
Early activation of pFAK is consistent with engagement of virus with integrin receptors as a
form of viral entry
To evaluate the role that the virus plays on FAK activation, we evaluated changes in
cellular FAK phosphorylation upon treatment with oHSVQ. Patient derived primary GBM
neurosphere cells (GBM12, GBM28, and GBM43) were plated on 6 well plates. Cells were
treated with the indicated OV at an MOI (multiplicity of infection) of 1 for an hour, after which
time unbound virus was washed off and cells were overlaid with media. Cell lysates from
infected and uninfected cells were collected 1 and 8 hours post infection and probed for
phosphorylated FAK by western blot analysis. Increased phosphorylation of FAK was observed
early after infection in both the cells which was then reduced by 8 hours post infection. AKT is a
central kinase that is downstream of FAK activation. To analyze changes in AKT pathway we
probed for changes in AKT phosphorylation in these samples. Consistent with early FAK
activation, we observed AKT phosphorylation as soon as an hour after infection. While FAK
activation was lost at later time points, AKT phosphorylation was sustained even at later times
after infection suggesting that FAK activation is temporal (Fig. 2).

8

Fig.2 Effects of oHSV on FAK activation/signaling
GBM12, GBM28, and GBM43 were treated with 1 MOI (multiplicity of infection) of HSVQ and Enve virus. Cell lysate was collected
and processed for western blot at two different timepoints post infection. Expression levels of pFAK and pAkt were assessed at each
time point. GAPDH was used as control.

Penfluridol reduces expression of integrin α6, αV, and pFAK in a dose dependent manner
Penfluridol has been shown to reduce integrin expression at a transcriptional level in
breast cancer models (10). To evaluate the role that Penfluridol plays on expression of integrin
and FAK signaling in glioma models, we analyzed changes in protein levels of integrin α6, αV,
and pFAK with different doses of Penfluridol treatment by western blot analysis. GBM12,
GBM43, and GBM1016 were plated on a six well plate and treated with three concentrations of
drug for 18 hours. Cell lysates were then collected and probed for integrin α6, αV, and pFAK.
We observed that Penfluridol treatment reduced the expression of integrins α6, αV, and pFAK in
a dose dependent manner in all three primary GBM models (Fig. 3a).

9

Fig.3 Effects of OV and PF on integrin expression and FAK signaling in GBM
(A) Western blot analysis in GBM cell lysates treated with PF for 18 hrs and virus +PF treatment for 24hrs (B) PF treatment
alone significantly reduced integrins αν and α6 as well as FAK phosphorylation. Virus +PF treatment reduces phosphorylation
of FAK as well as downstream targets such as Akt and Erk. GAPDH was used as loading control.

Combination treatment of Penfluridol and oHSV decreases activation of FAK, Akt and Erk.
FAK phosphorylation can lead to the activation of multiple downstream pathways that
allow for cell proliferation. Therefore, we evaluated the effects of combining our oHSV
treatment with Penfluridol. GBM1016, U87ΔEGFR, and T3 were plated on 6 well plates and
treated at an MOI of 1 for one hour. Unbound virus was washed away and cells were overlaid
with 2.5uM of Penfluridol. Cell lysates were collected 18 hours post infection and probed for
phosphorylated FAK by western blot analysis. Decreased pFAK expression was observed in
cells treated with combination of OV and Penfluridol. Additionally, we probed for
phosphorylated Akt as well as phosphorylated Erk to examine the effects of the combination
treatment on downstream targets in the FAK signaling pathway. We observed that the
combination treatment of oHSV and Penfluridol reduced expression of both pAkt and pErk (Fig.
3b).
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Penfluridol alone kills glioma cells in a dose dependent manner and when combined with
oHSV has an additive killing effect.
In addition to investigating the role that Penfluridol plays in attenuating integrin and FAK
signaling in glioma cells, we also examined the cytotoxicity of Penfluridol in glioma cells.
U87ΔEGFR, T3, GBM28 and GBM43 were plated on 96 well plates and treated with five
different concentrations of Penfluridol. Cells were treated with cell proliferation kit (Roche)
reagents 48 hours post treatment, and absorbance was measured using a Synergy HT Multi-Mode
Microplate reader (Biotek). Cell viability was measured as a percentage of uninfected control.
We observed that Penfluridol kills cells in a dose dependent manner in all cell lines (Fig. 4a).
Additionally, we examined the cytotoxicity of Penfluridol in combination with oHSV.
U87ΔEGFR, T3, GBM28 and GBM43 were plated on 96 well plates and treated with four
different MOIs of oHSVQ. One hour later, cells were overlaid with three different concentrations
of Penfluridol. Cells were treated with cell proliferation kit (Roche) reagents, either 24 or 48
hours post infection, and absorbance was measured using a Synergy HT Multi-Mode Microplate
reader (Biotek). We observed that the individual virus and drug treatments induced cytotoxicity;
however, when the two treatments were combined, we observed an additive or greater than
additive killing effect in all cell lines (Fig. 4b)
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Fig.4 Effects of PF and oHSV on tumor cell killing
A) Mean % cell killing of PF alone relative to uninfected cells (B) Mean % killing of virus +PF alone relative to
uninfected cells. Error bars indicate ± SD for each group. *, P < 0.05.

Penfluridol inhibits viral propagation at high concentrations in vitro
Since Penfluridol has an effect on integrin expression which are also important for viral
entry, we examined the effect of Penfluridol on viral propagation in vitro (7). T3, GBM12,
GBM28, and GBM43 cells were plated on 24 well plates and treated with an MOI of 0.5
oHSVQ. One hour later unbound virus was washed away, and cells were overlaid with five
different concentrations of Penfluridol. The plate was imaged every 4 hours for 48 hours using
the Cytation 5 live plate reader/imager (BioTek Instruments) to track GFP expression elicited by
our GFP encoded virus. Captured images were analyzed by BioTek Gen5 version 2.06 software
program, and GFP count was extracted and applied in Prism (GraphPad) to compare treatment
groups. Consistent with reduced integrin expression treatment of cells with higher concentrations
of PF inhibited viral spread in vitro (Fig. 5).
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Fig.5 Effects of Penfluridol on Viral Replication in vitro
A) Comparison of viral kinetics/replication between oHSV and oHSV+PF. Glioma cells were infected with oHSV (MOI=0.1) and viral
GFP expression was quantified for 48 hrs utilizing the Cytation 5 Live Cell Imaging.

Penfluridol does not inhibit viral replication in vivo
Based on the in vitro effects of combining Penfluridol and oHSV, we then proceeded to
examine the anti-tumor effects of combining PF treatment with OV in vivo. Athymic nude and
NSG mice were implanted with 1x10^5 GBM30 and GBM12 cells, respectively. Athymic nude
mice, bearing GBM30 tumors, were treated with PBS or 1x10^5 pfu of rHSVQ1-Luc
intratumorally 10 days post tumor implantation and began daily treatment of DMSO or 10mg/kg
of Penfluridol the following day. NSG mice, bearing GBM12 tumors, began daily treatment of
DMSO or 10mg/kg of Penfluridol 9 days post tumor implantation and were treated with PBS or
1x10^5 pfu of rHSVQ1-Luc intratumorally the following day (Fig 6a). For the three days
following intracranial virus treatment, bioluminescence imaging was performed to measure viral
replication via measuring virus encoded luciferase activity. Imaging data revealed that
Penfluridol did not inhibit viral replication in vivo (Fig. 6b).
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Fig.6 Effects of PF on viral replication in vivo
(A) Timeline of in vivo experiments (B) Mice bearing primary GBM30 and GBM12 intracranial tumors were treated with a single
intratumoral injection of 2 x 105 oHSV-Luc. Luciferase activity was measured by IVIS imaging

Penfluridol reduces migration of macrophage and microglia cells towards infected cells

Fig.7 Graphical representation of the effects of viral entry via integrins on the tumor microenvironment.

Engagement of viral proteins with integrin receptors not only activates FAK in tumor
cells, but also affects the tumor microenvironment (TME) by allowing for the transcription of
pro-inflammatory cytokines and anti-viral proteins as well as activation of an innate immune
14

response. Additionally, in macrophages, integrin 2 is important in allowing pro-inflammatory
effects to recruit and assist in immune cell migration (Fig. 7)(7, 25). Therefore, we examined the
effects of Penfluridol on macrophage and microglia migration towards infected cells using a
Boyden chamber assay. GBM8 cells were plated on the bottom of the Boyden chamber and
treated with the indicated oncolytic viruses (black bar) at an MOI of 1 for an hour. Unbound
virus was washed away and cells were then treated with or without Penfluridol. Two hours after
Penfluridol treatment, serum starved murine macrophage cells (Raw 264.7) or murine microglia
cells (BV2) were plated in the top chamber and allowed to migrate for 6 hours. Quantification of
migrated cells were accomplished by counting the number of cells/view field that migrated to the
bottom side of the transwell. Data shown are mean cells/view field ± s.d.The data showed that
upon virus infection there was an increase in number of Raw 264.7 and BV2 cells which had
migrated towards infected cells. However, when infected cells were treated with Penfluridol, the
number of migrated macrophage and microglia cells decreased significantly (Fig. 8a).
Tumor necrosis factor (TNFα) is a proinflammatory cytokine secreted predominantly by
macrophages but also other immune cells as well. TNF binds to two TNF receptors leading to
the downstream activation of both anti-apoptotic and proapoptotic pathways (11). We examined
the effect of Penfluridol on TNF secretion from macrophage and microglia cells. Raw 264.7
and BV2 cells were plated on 6 well plates and treated with Penfluridol for 24 hours.
Conditioned media was collected from each triplicate well and concentrations of secreted murine
TNF was measured using the murine TNFα DuoSet ELISA kit (R&D Systems). Serial dilutions
of a known concentration of purified recombinant murine TNFα were used to establish a
standard curve. Quantified data showed that Penfluridol treatment reduced secretion of murine
TNFα in both macrophage and microglia cells (Fig. 8b).
15

Combination treatment of oHSV and Penfluridol enhances survival in vivo
Based on the in vitro and in vivo data that was previously shown, we wanted to confirm
whether an overall therapeutic benefit was achieved when combining Penfluridol with our OV.
Thus, we tracked survival of mice bearing intracranial GBM30 or GBM12 mouse models treated
with PF and/or OV. Kaplan Meier survival curves showed that the combination treatment of
oHSV and Penfluridol significantly enhanced survival compared to individual treatments in both
the immune deficient mouse models.
Additionally, we examined the effects of OV and PF in immune competent mouse
models as well. The use of immune competent mice is beneficial as it allows us to investigate
effects of the host immune system on PF and OV therapy. Both effector and suppressor immune
cells can play a role in harming tumor cells or recruiting immune cells that are tumor supportive
(12). In our study we are interested in the effects that OV and PF can have on both the tumor and
the TME. Therefore, the use of an immune competent mouse model can help us assess these
effects by examining survival and potentially immune cell populations that are present in the
different treatment groups as well. We implanted 1x10^5 GL261N4 murine glioma cells into
C57BL/6 mice intracranially. Mice began daily treatment of DMSO or 10mg/kg of Penfluridol 9
days post tumor implantation and were treated with PBS or 1x10^5 pfu of rHSVQ1-Luc
intratumorally on day 10. Survival for mice was recorded and analyzed using a log-rank test to
compare survival curves for survival data, and Cox regression model was used to evaluate the
interaction between Penfluridol and oHSV on survival data. Survival in the combination
treatment was enhanced even further in the immune competent mouse model compared to
individual treatment groups (Fig. 9b and c).
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Fig.9 Effects of oHSV and PF on survival in vivo
(A) Kaplan- Meier survival data of GBM30-Luc and GBM12. Intracranial GBM-bearing mice were injected with oHSV by intratumoral injection.
DMSO/PF (10mg/kg) were treated by daily oral gavage during study. Significant reduction in tumor growth in PF and oHSV combination-treated
mice (B) Intracranial GL261-N4-bearing C57BL/6 mice were injected with oHSV by intratumoral injection and DMSO/PF (10mg/kg) were
treated by daily oral gavage. Significantly enhanced mice survival rate in combination-treated mice
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Discussion & Conclusion
Due to its invasive nature and volatile tumor microenvironment (TME) the need for
effective therapeutics against glioblastoma (GBM) is necessary in order to improve survival in
patients (2). Oncolytic viral (OV) therapy has shown promise in the lytic destruction of cancer
cells, specifically in melanoma for which it is currently FDA approved as a form of therapy (4,
5). However, a concern regarding OV therapy is the risk that the virus can activate pathways that
cause viral clearance and promote tumor growth. In this study, we examined the role of integrins
in viral entry and how their enagagement can ultimately lead to the activation of FAK. Integrins
are made up of an α and β subunit and bind extracellular matrix proteins thereby regulating cell
adhesion and signaling across the cellular membrane (6). In GBM, a negative correlation has
been seen between overexpression of integrins in GBM and overall survival. αVβ3 and αVβ5
integrins were first discovered to be therapeutic targets for GBM as they are not expressed on
normal brain tissue but instead found solely on tumor associated endothelial cells and GBM
cells. Malric et al., conducted a statistical analysis based on TCGA Affymetrix data to determine
the relationship between integrin expression and overall survival in GBM patients. They found
that patients with primary GBM tumors that had overexpression of β1, β3, α3, α5, and αV had a
decreased overall survival (6). Campadelli et al., found that expression of αVβ3, αVβ6, and
αVβ8, is vital in initiating virus entry (REF HERE). These three receptors bind to the gH/gL
complex on the viron envelope to allow the virus to enter the cell. Additionally, αVβ6 and αVβ8
bind the gH/gL complex at a higher affinity than αVβ3. Furthermore, blocking or depletion of
either β6 or β8 integrins results in the inhibition of viral entry, which emphasizes the significance
of these integrins in viral entry (7). Integrin activation can ultimately lead to the activation of
numerous downstream pathways that can allow for tumor growth and metastasis. One of the
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major downstream targets is Focal Adhesion Kinase (FAK). Stimulation of FAK by integrins
promotes what is called FAK-survival to allow evasion of cell death (13). In this paper, we
examined the effects of viral infection on FAK activation at two timepoints following infection
through western blotting analysis. Figure 2a shows activation of FAK 1 hour post infection as
well as activation of Akt. At 8 hours post infection however, there is a decrease in FAK
activation while Akt activation is sustained. This result suggests that FAK activation is temporal
and that integrin-mediated viral entry can lead to activation of FAK at an early time point.
Additionally, activation of Akt, a downstream target of FAK, was seen at both early and later
timepoints suggesting that Akt activation may be independent of the FAK signaling pathway
(13).
Since FAK activation can result in the activation of multiple downstream targets that
promote cell invasion, metastasis, angiogenesis, and resistance to apoptosis (14), we investigated
the use of Penfluridol (PF) , an FDA approved antipsychotic that has been shown to attenuate
integrin-FAK signaling on oncolytic viral herapy (10). PF was developed in 1963 and functions
as a long-acting drug by being deposited in fatty tissue after absorption in the GI tract and being
slowly released over time (15). Therefore, the drug is given weekly to patients. As an
antipsychotic, it functions as a dopamine antagonist by blocking the dopaminergic receptor
membranes (16). The repurposing of PF as a potential cancer therapeutic is something that has
previously been explored and has been shown to elicit cytotoxic effects against breast-brain
metastasis and GBM, as well as downregulation of integrin 6 and 4 at a transcriptional level
(9, 10). From this finding, we investigated the effects that PF would have on integrin and pFAK
expression in primary GBM cells. Using western blot analysis, we specifically focused on
expression levels of integrin V and 6 as well as activation of FAK. We saw that Penfluridol
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reduces expression of both integrin V and 6 in a dose dependent manner and also reduced
activation of pFAK in a dose dependent manner. Due to the fact that virus infection can activate
FAK and Akt we were interested in the effects that the combination treatment of OV and PF
would have on this signaling pathway and its downstream targets. Through western blot analysis
we examined the activation of FAK, Akt and Erk with OV and PF as individual treatments and
as a combination treatment. In all three GBM cell lines, the combination treatment group reduced
activation of FAK as well as Akt and Erk. This result illustrates the idea that PF can assist in
attenuating the activation of certain signaling pathways that would normally be upregulated upon
virus infection.
In addition to the therapeutic advantage that OV and PF offer as a combination treatment,
we also examined the effects of both agents on tumor cell killing, virus replication and the tumor
microenvironment. It has previously shown that PF has cytotoxic effects in breast-brain
metastasis and GBM models (9, 10) and increases expression of cell cycle arrest and proapoptotic proteins (18). We assessed PF’s cytotoxicity as a single agent and in combination with
OV on GBM cells in our own hands by using a cell proliferation assay. Figure 4a illustrates the
fact that cell killing occurs in a dose dependent manner across all cell lines that were tested in
vitro, however this did not translate into an in vivo efficacy as a single agent. Additionally, when
PF was combined with oncolytic HSV we see that both OV and PF are effective at killing cells
as single agents, however when combined they display an additive, if not more than additive,
killing effect. Due to the fact that PF has been shown to reduce transcriptional expression of
integrins we wanted to examine the effect PF has on viral propagation. As stated earlier,
integrins play a critical role in virus entry and propagation, specifically through αVβ6 and αVβ8
(7). PF has been shown to attenuate integrin 6 and 4 expression and though their targets are
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not the same, we wanted to examine whether or not PF may have an effect on viral entry in vitro.
Using the Cytation 5 live plate reader/imager (BioTek), we tracked viral propagation through
GFP expression for 48 hours. The data showed that there was a reduction in viral propagation in
a dose and time dependent manner in all 4 cell lines. We noticed was that viral propagation
began to reduce more significantly at higher drug concentrations at 12-16 hours post infection.
During the treatment, we treated the cells with virus for one hour before washing away unbound
virus and overlaying with drug. Therefore, the initial virus infection could not be attenuated by
PF. However, during the second infection, which would occur around 16 hours post infection,
the increase in GFP was not as great in the groups treated with higher concentrations of PF. This
result is consistent with the fact that PF can downregulate integrin expression and because
integrins are important for viral entry; the presence of PF may play a role in decreasing viral
propagation over time.
We investigated the effects of PF further by testing the drug in combination with the
virus in vivo. Immune deficient (athymic nude and NSG) mice were implanted with GBM30 and
GBM12 tumors respectively and treated with PF or virus as singular agents or treated with both
agents as a combination therapy. To compare viral replication in vivo between virus alone and
virus + PF groups, bioluminescence imaging was conducted to track viral replication for three
days in both models. Contrary to what is seen in vitro, there is no inhibition of viral replication in
vivo in either mouse model. The rationale behind this difference in in vitro and in vivo result
could be due to the ability for PF to successfully reach the tumor at the same concentration that it
was given. The blood brain barrier (BBB) plays a critical role in dictating what can and cannot
reach the brain and has multiple transporters and pumps that help regulate the homeostasis of the
brian. This tight regulation has been a hurdle when it comes to drug delivery to the brain (19).
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ATP-binding cassette (ABC) Transporters are abundant in the BBB and assist in maintaining
lipid bilayers and transporting peptides and sterols across the BBB. However, ABC transporters
are of particular interest due to the fact that they have been known to play a role in the
development of a multidrug resistance (MDR) phenotype (20). Overexpression of Pglycoportein, which is encoded by the MDR gene, is thought to have been an evolutionary
mechanism put in place protect the brain. In fact, it was seen that knockdown of
MDR1a/MDR1b in mice caused a 100 fold increase in uptake of neurotoxins (20). Although
Rajan et al stated that they saw 72% tumor inhibition upon treatment of PF in an intracranial
model and that there is BBB penetrability by PF (10), there is little evidence that illustrates how
much PF actually reaches the brain. A paper published in 1979 by Grindel et al., examined how
PF was metabolized in rabbits, rats, dogs and humans. They examined percent dose of PF per
organ, after 24 hours, by tagging the drug with a radioactive isotope and measuring radioactivity
in each organ in rats. On average the percent dose of PF that reached the brain was less than 1%
when given orally (5mg/kg) and through i.v (2mg/kg) (21). Another method by which we can
assess how much PF has reached the brain would be to harvest the brains of PF treated mice and
perform mass spectrometry analysis to determine the amount of PF present after treatment. After
determining the concentration of PF that reaches the brain we can test that concentration in vitro
to determine if it is enough to inhibit viral replication. Additionally, if PF penetration is actually
limited by the BBB and its transporters, knocking down the MDR1a/MDR1b gene and tracking
survival as well as comparing PF in the brain through mass spectrometry between MDR null and
wild type could illustrate the limitations of drug delivery through the BBB.
We continued to investigate the role of PF by examining its effects on the tumor
microenvironment (TME). Campadelli et al., discuss the fact that activation of integrins upon
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viral entry can ultimately lead to the activation and recruitment of immune cells and cytokines
that can encourage viral clearance (7). Therefore, we examined the effects of PF on macrophage
and microglial migration towards infected tumor cells. Our results showed that PF significantly
reduced migration of macrophage and microglia towards infected cells and that PF treatment
reduced secretion of TNF from macrophage and microglia, implying that…. Despite these
findings, it is still unclear as to whether the reduction in recruitment of macrophage and
microglia is due to the attenuation of integrin and FAK signaling. To test this hypothesis, we
could knock down FAK expression or block it in GBM cells and evaluate of the expression of
cytokines such as TNF and IFN as well as immune cell migration. If knockdown of FAK is
not sufficient to suppress cytokine secretion and immune cell infiltration then it is possible that
FAK is not the major pathway that regulates this response. We could also attempt to block
integrin activation to see whether or not integrin activation is important in the downstream
expression of proinflammatory cytokine secretion and immune cell infiltration. Additionally, the
fact that PF can reduce anti-viral cytokines in the TME should increase viral replication in vivo.
However, because it is unclear as to how much PF can successfully reach the brain, this may be
the rationale behind why we did not see a significant increase in viral replication in vivo.
In addition to examining viral replication in vivo we also looked into the effects of OV
and PF on overall survival in vivo. Three different mouse models were used in this study to track
survival, athymic nude and NSG which are immune deficient and C57BL/6 which is immune
competent. The results showed that the combination treatment of OV and PF significantly
improved survival in both immune competent and immune deficient models compared to the
individual treatments alone.. Six mice in the syngeneic immune competent model continued on
to be long term surviors (survival >100 days) and were included in a rechallenge experiment.
23

Ultimately, there was no difference in survival between rechallenged and naïve mice and
therefore we concluded that there was no formation of an immune memory response that could
result in subsequent tumor rejection. However, it is possible that there is anti-tumor immunity
without complete rejection of the tumor. To test this hypothesis, we can implant the same tumor
model (GL261N4) into athymic nude mice and examine the therapeutic efficacy of PF in
combination with OV and examine if these effects are dependent on the TME.
Since the effects of PF on the TME have not been thoroughly explored, it is important to
consider the reasons why we may not have seen an anti-tumor memory response in our immune
competent model to better understand the potential limitations of PF as a cancer therapeautic.
Macrophages and T cells play an important role in activating an effective adaptive anti-tumor
immune response (22). In cancer biology, macrophages, specifically tumor associated
macrophages (TAMs), are one of the most common cells found in the TME of solid tumors and
often correlate with poor prognosis in several different cancers. They are part of the innate
immune response and act by blocking immune mediated clearance of tumor cells and engage
directly with tumor cells to initiate pro-surival signaling pathways. Macrophages also encourage
tumor progression by releasing cytokines, such as IL-6, that can activate anti-apoptotic pathways
and induce angiogenesis through the production of vascular endothelial growth factor (VEGF)
(23). Additionally, macrophages can differentatiate into two different phenotypes: M1 and M2.
M1 macrophages respond to interferon gamma (IFN) and lipopolysaccharide (LPS) and are
known to elicit a proinflammatory response. M2 macrophages on the other hand, respond to IL-4
or IL-13 and produce an anti-inflammatory response therefore encouraging tissue remodeling
and a protumorigenic environment (24). Macrophages are known to express integrins,
specifically integrin 2, which is expressed primarily on leukocytes. When interacting with their
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 subunit, integrin 2 can activate three distinct functions: immune cell recruitment, immune cell
interactions and immune cell signaling (25). Based on previous papers and our data, we know
that PF is capable of downregulating the expression of integrins, specifically V and 6.
However, the specificity of PF in targeting integrins is unknown and therefore PF could have an
effect on the expression of numerous integrins including those found on immune cells in the
TME. In the case of macrophages, integrin 2 is important in allowing pro-inflammatory effects
to recruit and assist in immune cell migration (25). If PF attenuates expression of integrin 2 in
the immune competent mouse model this can be benficial in reducing viral clearance and
therefore allowing for further viral propagation. However, PF’s blockade of integrin 2 may also
reduce pro-inflammatory effects and migration of immune cells thereby preventing the induction
of an adaptive immune response. This second rationale may also be a contributing factor as to
why we did not see a strong adaptive immune response. We can test this hypothesis by
harvesting brain tissue of mice with OV, PF and OV+PF treatment and staining for specific
immune cell populations using flow cytometry. Additionally, we can test the in vitro effects of
PF on cytokine expression using an antibody array to check protein expression of numerous proinflammatory cytokines that recruit immune cells to the TME and also using qPCR to assess
changes in gene expression of cytokine levels.
T cells are the second most common immune infiltrate in the TME and are a key player
in the adaptive immune response. In the early stages of tumor development, T cells elicit an
effector response to eradicate immunogenic cancer cells. Therefore a high level of effector T cell
infiltration correlates with a better prognosis in numerous cancer types. These effector T cells
include cytotoxic T cells, which directly destroy cells by releasing perforins and granzymes
causing cell lysis, and helper T cells, which indirectly target cells by secreting cytokines to
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recruit immune cells to the TME. As the tumor grows and the TME evolves, recruitment of
regulatory T cells (Tregs) can occur, suppressing anti-tumor effects. Tregs are group of T cells
known as suppressor cells and function by activating signaling mechansims that enhance the
recruitment of immunosuppressive cytokines and molecules which ultimately leads to a decrease
in activation of effector T cells (26). Similar to macrophages, T cells also express integrins
which play a role in T cell signaling and differentiation. Expression of integrins on T cells can
change throughout the lifecyle of the cell however, the most commonly found integrins include
4, L, 5, 6, V and 1, 2, 7 and 3 (27). One importance of integrins in T cells is the role
they play in thymocyte differentiation. L2, 41, 51 are important integrins that initiate
differentiation of CD4+/CD8+ thymocytes by binding to ICAM-1, VCAM-1 and fibronectin
repectively. In addition to assisting with T cell differentiation, L2 on naïve T cells, can
interact with endothelial cells by binding with ICAM-1 to become a “primed” form of L2
ultimately causing T cell arrest and the production of matrix metalloproteinases (MMPs) (27).
The interaction between L2 and ICAM-1 can be beneficial for T cell migration, however, the
release of MMPs into the TME can lead to tumor cell growth and metastasis. MMPs particulary
play a role in the development of a pre-metstatic niche by remodeling the extracellular matrix of
tumors and recruiting cells and factors that further contribute to metastatic colonization (28). As
stated earlier, the specificity of PF on certain integrins is unknown, however we can test PF’s
effects on L2 expression using western blot analysis and by examining gene expression of
MMPs by doing qPCR on tumor cells cocultured with human PBMCs with and without PF
treatment. If PF can reduce expression of MMPs, it is possible that PF can contribute to reducing
tumor metastasis as well. On the other hand, because L2 plays an important role in T cell
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differentiation, the blocking of L2 by PF may result in reduced T cell maturation and
production.
Another aspect of this study that is important to address is the translational purpose and
potential pitfalls of the use of PF as an anti-cancer treatment. As I mentioned earlier in the
discussion, the repurposing of PF as an anti-cancer drug is a concept that has been explored. One
thing to take into consideration when using a drug is the dosage and side effects associated with
it. PF is an antipsychotic with a long half-life and, through clinical research, has a suggested dose
is 40-80 mg/week to see clinical improvement (29). However, in order to exhibit anti cancer
effects much higher concentrations of PF need to be used. It has been published that between
4.5-10umol/L is the IC50 for GBM(30) and in our own study we have seen that 4-5uM of PF
was the IC50 dose which again are significantly higher than the doses given to patients to treat
psychosis. The pitfall to using a higher concentration of PF to treat cancer patients is the
neurological side effects that may be exhibited such as epilepsy, depression, dyskinesias,
dystonia, and fatigue (30). When we began drug treatment with our in vivo models our dosing
was 10mg/kg everyday until the mouse was sacrificed which is equivalent to a 50 mg dose
everyday in humans. Overall, this exceeds the recommended dose even in patients with severe
psychosis and can be a concern due to the neurological side effects associated with PF.
Therefore, it is important that we examine the direct mechanistic effects of PF as an anti cancer
drug and determine if there are ways that PF can be modified to elicit less side effects and
toxicity while retaining it’s capabilities as a cancer therapeutic.
As an antipsychotic PF functions by blocking dopamine receptors specifically dopamine
receptor 2 (D2) (30). From here, the first question we could ask is whether or not there is
relationship between dopamine receptor 2 and cancer and if so could this be the reason why PF is
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effective in killing tumor cells. As far as what is known about PF as an anti cancer drug it is seen
to lower transcriptional expression of integrin alpha 6, induce cell death, reduce cell proliferation
and invasion and even suppress T regulatory cells. However, a direct mechanism of anti cancer
activity by PF has not been proven and it’s anti cancer effects were seen predominatly at
concentrations that are significantly higher than those that are typically given to patients.
Therefore, development of PF derivatives with lower antipsychotic effects and enhanced anti
cancer effects could be highly significant. This concept is key because it is important to
understand the direct mechanism of action for a drug so that it can be fine tuned to maximize
therapeutic benfit while minimizing unwanted side effects. Ashraf-Uz-Zaman et al hypothesized
that leveraging the pharmacophores activities to promote anti cancer effects and reducing the
effects of PF on G protein coupled receptors (GPCRs) can make PF a safer and more effect caner
therapeutic (31). Ultimately, they identified two modified compounds that exhibited less effects
on the CNS and retained their anti cancer effects at a lower IC50 concentration than traditional
PF. When testing these compounds in vivo, they treated mice with a dose of 5mg/kg for 7 days,
instead of the usual 10mg/kg, and saw that one of the compounds reached the brain better than
traditional PF. For the purposes of our study, we could examine whether or not these PF
derivatives can elicit the same cytotoxicity in vivo while also enhancing viral replication instead
of inhibiting it, therefore giving off a more synergistic effect. We can test this by using a cell
proliferation assay and comparing killing in combination treatment groups, as well as assess viral
replication with the PF derivative via our Cytation 5 machine through GFP count. Addtionally,
since we hypothesize that traditional PF may have a more direct effect on the TME vs tumor
cells we could also examine whether the PF derivative compound has the same effects on the
TME as traditional PF and whether it improves survival in vivo as well.
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In conclusion, our study highlights one aspect of the mechanistic effects of viral entry
and infection and how this effect can be attenuated by FDA approved Penfluridol (PF). We
showed that PF is sufficient at reducing integrin expression and FAK activation as well as
increasing tumor cell killing when combined with oncolytic HSV. We also showed the effects of
PF and OV in vivo by examining the combined agents’ therapeautic efficacy. Overall, survival
was significantly higher in the combination treated groups compared to individual treatments.
Future directions for this study involve examining the effects of PF on immune cell infiltration in
the TME by looking at whether or not PF attenuates integrin signaling on immune cells and to
gain a better understanding as to the overall role of integrin signaling is in the TME as a tumor
progresses.
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